22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › NEUROGENE INC. › 2024-2025

NEUROGENE INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and NEUROGENE INC.’s Form 8-K, filed June 12, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 106Asset managers, any item
  • 698Fund votes
  • June 12, 2025Meeting date

Results at a glance

Meeting of June 12, 2025: 6 items on NEUROGENE INC.’s Form 8-K, filed June 12, 2025: 6 passed (calculated).

Dissent

Significant dissent: 1 equity or compensation plan (26.0% against).

Notable dissent: 1 say-on-pay vote (70.9% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore NEUROGENE INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by NEUROGENE INC.

These tallies are NEUROGENE INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

NEUROGENE INC. — official shareholder meeting results, meeting held June 12, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Sarah B. Noonberg 10,344,227---- 656,571480,734 94%Passed (calculated)—
Elect Director: Robert "Keith" Woods 10,444,580---- 556,218480,734 95%Passed (calculated)—
2. Approval on an advisory (non-binding) basis of the compensation of the Company's named executive officers 7,721,8663,174,484104,448 --480,734 71%Passed (calculated)—
3. Approval of an amendment to the Company's 2023 Equity Incentive Plan to clarify that the number of outstanding shares of common stock used to calculate the automatic share reserve increase also includes shares issuable on exercise of prefunded warrants and 8,067,7462,829,550103,502 --480,734 74%Passed (calculated)—
4. Approval of an amendment to the Company's 2023 Employee Stock Purchase Plan to clarify that the number of outstanding shares of common stock used to calculate the automatic share reserve increase also includes shares issuable on exercise of prefunded warran 10,794,908101,329104,561 --480,734 99.1%Passed (calculated)—
5. Ratification on an advisory (non-binding) basis of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 11,372,32710,33398,872 ---- 99.9%Passed (calculated)—

Source: NEUROGENE INC., Form 8-K, filed with the SEC on June 12, 2025 — read the filing on EDGAR.

How asset managers voted at the NEUROGENE INC. 2024-2025 meeting

106 asset managers disclosed a vote on at least one NEUROGENE INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Robert "Keith" Woods

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 10,444,580WITHHELD: 556,218
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: Election of Class II Directors for terms expiring in 2028: Robert Keith Woods

NEUROGENE INC.’s own tally for this item (“Elect Director: Robert "Keith" Woods”): 10,444,580 for, 556,218 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 629,332 for, 27,123 withheld, 138 abstained.

FOR
FOR: 629,332ABSTAIN: 138WITHHOLD: 27,123
Largest asset managers voting on “Election of Class II Directors for terms expiring in 2028: Robert Keith Woods” at NEUROGENE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock405,1160 00For
Fidelity86,9740 00For
Vanguard51,9870 00For
JPMorgan30,9480 00For
Lincoln Financial15,7680 00For
Equitable2,0820 06,710Mixed
Northern Trust8,7880 00For
AIG/SunAmerica00 07,482Withhold
Global X6,8470 00For
Charles Schwab5,7900 00For
Pacific Life4,5720 00For
ETFis Series Trust I00 04,159Withhold
Bridge Builder Trust3,5880 00For
Voya00 02,046Withhold
SEI1,7000 00For
State Street1,6580 00For
ProShares00 01,650Withhold
Victory Capital00 01,475Withhold
DWS00 01,099Withhold
Calvert00 01,009Withhold
Franklin Templeton1,0030 00For
Columbia Threadneedle8180 00For
Dimensional00 0721Withhold
Nationwide5040 00For
QUANTITATIVE MASTER SERIES LLC3960 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Elect Director: Sarah B. Noonberg

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 10,344,227WITHHELD: 656,571
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: Election of Class II Directors for terms expiring in 2028: Sarah B. Noonberg

NEUROGENE INC.’s own tally for this item (“Elect Director: Sarah B. Noonberg”): 10,344,227 for, 656,571 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 186,618 for, 60,875 withheld, 409,100 abstained.

FORABSTAIN
FOR: 186,618ABSTAIN: 409,100WITHHOLD: 60,875
Largest asset managers voting on “Election of Class II Directors for terms expiring in 2028: Sarah B. Noonberg” at NEUROGENE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock00 405,1160Abstain
Fidelity86,9740 00For
Vanguard00 051,987Withhold
JPMorgan30,9480 00For
Lincoln Financial15,7680 00For
Equitable6,7100 02,082Mixed
Northern Trust8,7880 00For
AIG/SunAmerica7,4820 00For
Global X6,8470 00For
Charles Schwab5,7900 00For
Pacific Life00 04,572Withhold
ETFis Series Trust I4,1590 00For
Bridge Builder Trust00 3,5880Abstain
Voya2,0460 00For
SEI1,7000 00For
State Street1,6580 00For
ProShares1,6500 00For
Victory Capital1,4750 00For
DWS1,0990 00For
Calvert00 01,009Withhold
Franklin Templeton1,0030 00For
Columbia Threadneedle8180 00For
Dimensional00 0721Withhold
Nationwide00 0504Withhold
QUANTITATIVE MASTER SERIES LLC00 3960Abstain

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Approval of an amendment to the Company's 2023 Employee Stock Purchase Plan to clarify that the number of outstanding…

Calculated outcomeCOMPENSATIONPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 10,794,908AGAINST: 101,329
Details: description as filed, official tally, votes by 35 asset managers

Description as filed by funds: To approve an amendment to our 2023 Employee Stock Purchase Plan to clarify that the number of outstanding shares of common stock used to calculate the automatic share reserve increase includes shares issuable on exercise of prefunded warrants and conversion of preferred stock.

NEUROGENE INC.’s own tally for this item (“4. Approval of an amendment to the Company's 2023 Employee Stock Purchase Plan to clarify that the number of outstanding shares of common stock used to calculate the automatic share reserve increase also includes shares ”): 10,794,908 for, 101,329 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 35 asset managers below reported 130,204 for, 526,393 against.

FORAGAINST
FOR: 130,204AGAINST: 526,393
Largest asset managers voting on “To approve an amendment to our 2023 Employee Stock Purchase Plan to clarify that the number of outstanding sha” at NEUROGENE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock0405,116 00Against
Fidelity66,56620,408 00Mixed
Vanguard51,9870 00For
JPMorgan030,948 00Against
Lincoln Financial9,1006,668 00Mixed
Equitable08,792 00Against
Northern Trust08,788 00Against
AIG/SunAmerica07,482 00Against
Global X06,847 00Against
Charles Schwab05,790 00Against
Pacific Life04,572 00Against
ETFis Series Trust I04,159 00Against
Bridge Builder Trust03,588 00Against
Voya02,046 00Against
SEI01,700 00Against
State Street1,6580 00For
ProShares01,650 00Against
Victory Capital01,475 00Against
DWS01,099 00Against
Calvert01,009 00Against
Franklin Templeton01,003 00Against
Columbia Threadneedle0818 00Against
Dimensional0721 00Against
Nationwide0504 00Against
QUANTITATIVE MASTER SERIES LLC0396 00Against

Showing the 25 largest of 35 asset managers. All 35 are in the interactive database (link above).

Approval of an amendment to the Company's 2023 Equity Incentive Plan to clarify that the number of outstanding shares…

Calculated outcomeCOMPENSATIONPassed (calculated)

Combines 2 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%AGAINST
FOR: 8,067,746AGAINST: 2,829,550
Details: description as filed, official tally, votes by 35 asset managers

Description as filed by funds: To approve an amendment to our 2023 Equity Incentive Plan to clarify that the number of outstanding shares of common stock used to calculate the automatic share reserve increase includes shares issuable on exercise of prefunded warrants and conversion of preferred stock.

NEUROGENE INC.’s own tally for this item (“3. Approval of an amendment to the Company's 2023 Equity Incentive Plan to clarify that the number of outstanding shares of common stock used to calculate the automatic share reserve increase also includes shares issuabl”): 8,067,746 for, 2,829,550 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 35 asset managers below reported 656,597 against.

AGAINST
AGAINST: 656,597
Largest asset managers voting on “To approve an amendment to our 2023 Equity Incentive Plan to clarify that the number of outstanding shares of ” at NEUROGENE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock0405,116 00Against
Fidelity086,974 00Against
Vanguard051,987 00Against
JPMorgan030,948 00Against
Lincoln Financial015,768 00Against
Equitable08,792 00Against
Northern Trust08,788 00Against
AIG/SunAmerica07,482 00Against
Global X06,847 00Against
Charles Schwab05,790 00Against
Pacific Life04,572 00Against
ETFis Series Trust I04,159 00Against
Bridge Builder Trust03,588 00Against
Voya02,046 00Against
SEI01,700 00Against
State Street01,658 00Against
ProShares01,650 00Against
Victory Capital01,475 00Against
DWS01,099 00Against
Calvert01,009 00Against
Franklin Templeton01,003 00Against
Columbia Threadneedle0818 00Against
Dimensional0721 00Against
Nationwide0504 00Against
QUANTITATIVE MASTER SERIES LLC0396 00Against

Showing the 25 largest of 35 asset managers. All 35 are in the interactive database (link above).

Approval on an advisory (non-binding) basis of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 10 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%AGAINST
FOR: 7,721,866AGAINST: 3,174,484

Prior year: 95.0% for (June 14, 2024 meeting) ▼ 24.1 pts

Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: To approve on an an (non-binding) basis the compensation of the Company's named executive officers.

NEUROGENE INC.’s own tally for this item (“2. Approval on an advisory (non-binding) basis of the compensation of the Company's named executive officers”): 7,721,866 for, 3,174,484 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 34 asset managers voting on “To approve on an an (non-binding) basis the compensation of the Company's named executive officers.” at NEUROGENE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock405,1160 00For
Fidelity86,9740 00For
Vanguard51,9870 00For
JPMorgan30,9480 00For
Lincoln Financial15,7680 00For
Equitable8,7920 00For
Northern Trust8,7880 00For
AIG/SunAmerica7,4820 00For
Global X6,8470 00For
Charles Schwab5,7900 00For
Pacific Life4,5720 00For
ETFis Series Trust I4,1590 00For
Bridge Builder Trust3,5880 00For
Voya2,0460 00For
SEI1,7000 00For
State Street1,6580 00For
ProShares1,6500 00For
Victory Capital1,4750 00For
DWS1,0990 00For
Calvert01,009 00Against
Franklin Templeton1,0030 00For
Columbia Threadneedle8180 00For
Dimensional0721 00Against
Nationwide5040 00For
QUANTITATIVE MASTER SERIES LLC3960 00For

Fund voting reports, all 34 managers: 654,863 for, 1,730 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 85 asset managers voting on “To approve on an an (non-binding) basis the compensation of the Company's named executive officers.” at NEUROGENE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Samsara BioCapital, LLC1,717,1270 00For
Redmile Group, LLC1,285,1790 00For
EcoR1 Capital, LLC1,186,3810 00For
RTW INVESTMENTS, LP1,133,6560 00For
BAKER BROS. ADVISORS LP962,7400 00For
Commodore Capital LP925,0000 00For
GREAT POINT PARTNERS LLC491,7920 00For
Casdin Capital, LLC418,1590 00For
ArrowMark Colorado Holdings LLC371,4730 00For
Octagon Capital Advisors LP201,1480 00For
JENNISON ASSOCIATES LLC108,0840 00For
BLAIR WILLIAM & CO/IL106,9240 00For
Rock Springs Capital Management LP104,3390 00For
State Street89,36928 00For
Woodline Partners LP83,4100 00For
BlackRock80,121911 00For
JPMorgan76,1120 00For
Fidelity75,6220 00For
Northern Trust54,9470 00For
DAFNA Capital Management LLC51,5000 00For
DRIEHAUS CAPITAL MANAGEMENT LLC32,7650 00For
ADAR1 Capital Management, LLC25,7360 00For
Wellington25,0430 00For
MELLON INVESTMENTS Corp24,2610 00For
GEODE CAPITAL MANAGEMENT, LLC22,8620 00For

Institutional-manager reports, all 85 managers: 9,754,589 for, 13,060 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification on an advisory (non-binding) basis of the appointment of Deloitte & Touche LLP as the Company's…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 11,372,327AGAINST: 10,333
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To ratify on an advisory (non-binding) basis the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.

NEUROGENE INC.’s own tally for this item (“5. Ratification on an advisory (non-binding) basis of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025”): 11,372,327 for, 10,333 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 656,593 for.

FOR
FOR: 656,593
Largest asset managers voting on “To ratify on an advisory (non-binding) basis the appointment of Deloitte & Touche LLP as the Company's indepen” at NEUROGENE INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock405,1160 00For
Fidelity86,9740 00For
Vanguard51,9870 00For
JPMorgan30,9480 00For
Lincoln Financial15,7680 00For
Equitable8,7920 00For
Northern Trust8,7880 00For
AIG/SunAmerica7,4820 00For
Global X6,8470 00For
Charles Schwab5,7900 00For
Pacific Life4,5720 00For
ETFis Series Trust I4,1590 00For
Bridge Builder Trust3,5880 00For
Voya2,0460 00For
SEI1,7000 00For
State Street1,6580 00For
ProShares1,6500 00For
Victory Capital1,4750 00For
DWS1,0990 00For
Calvert1,0090 00For
Franklin Templeton1,0030 00For
Columbia Threadneedle8180 00For
Dimensional7210 00For
Nationwide5040 00For
QUANTITATIVE MASTER SERIES LLC3960 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Largest NEUROGENE INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 14,262,066 shares outstanding at the time of that meeting.

Fund voting reports: top NEUROGENE INC. shareholders by shares voted on “To approve on an an (non-binding) basis the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1BlackRock 2.84%
2Fidelity 0.61%
3Vanguard 0.36%
4JPMorgan 0.22%
5Lincoln Financial 0.11%
6Equitable 0.06%
7Northern Trust 0.06%
8AIG/SunAmerica 0.05%
9Global X 0.05%
10Charles Schwab 0.04%
Institutional-manager reports: top NEUROGENE INC. shareholders by shares voted on “To approve on an an (non-binding) basis the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Samsara BioCapital, LLC 12.04%
2Redmile Group, LLC 9.01%
3EcoR1 Capital, LLC 8.32%
4RTW INVESTMENTS, LP 7.95%
5BAKER BROS. ADVISORS LP 6.75%
6Commodore Capital LP 6.49%
7GREAT POINT PARTNERS LLC 3.45%
8Casdin Capital, LLC 2.93%
9ArrowMark Colorado Holdings LLC 2.60%
10Octagon Capital Advisors LP 1.41%

Reported NEUROGENE INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

NEUROGENE INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Samsara BioCapital, L.P.1,731,671 —Proxy statement (DEF 14A), proxy filed April 25, 2025
Redmile Group, LLC1,557,179 —Schedule 13G, filed February 17, 2026
RTW Investments, LP1,498,829 —Schedule 13G, filed February 14, 2025
Entities affiliated with EcoR1 Capital Fund, L.P.1,443,413 —Proxy statement (DEF 14A), proxy filed April 25, 2025
EcoR1 Capital, LLC1,442,902 —Schedule 13G, filed November 14, 2025
Entities affiliated with Redmile Group, LLC1,438,033 —Proxy statement (DEF 14A), proxy filed April 25, 2025
Entities affiliated with RTW Investments, LP1,434,645 —Proxy statement (DEF 14A), proxy filed April 25, 2025
Rachel McMinn1,320,021 —Proxy statement (DEF 14A), proxy filed April 25, 2025
Casdin Capital, LLC1,295,361 —Schedule 13G, filed February 14, 2025
Entities affiliated with Casdin Capital, LLC1,295,361 —Proxy statement (DEF 14A), proxy filed April 25, 2025

Percentages above are of 14,262,066 shares outstanding, as reported by NEUROGENE INC. on its Form 10-Q dated May 5, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At NEUROGENE INC.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 106 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 698 separate fund positions. On the most widely held item on that ballot — To approve on an an (non-binding) basis the compensation of the Company's named executive… — FOR was 71% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: NEUROGENE INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NEUROGENE INC.’s 10-Q dated May 5, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

NEUROGENE INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “NEUROGENE (NGNE) 2025 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/neurogene-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.